Amicus Therapeutics/$FOLD
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Amicus Therapeutics
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Ticker
$FOLD
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
499
ISIN
US03152W1099
Website
FOLD Metrics
BasicAdvanced
$1.9B
-
-$0.10
0.79
-
Price and volume
Market cap
$1.9B
Beta
0.79
52-week high
$12.19
52-week low
$5.51
Average daily volume
5.3M
Financial strength
Current ratio
3.341
Quick ratio
2.217
Long term debt to equity
224.689
Total debt to equity
229.113
Interest coverage (TTM)
0.98%
Profitability
EBITDA (TTM)
56.018
Gross margin (TTM)
90.60%
Net profit margin (TTM)
-5.41%
Operating margin (TTM)
8.80%
Effective tax rate (TTM)
-812.77%
Revenue per employee (TTM)
$1,090,000
Management effectiveness
Return on assets (TTM)
3.95%
Return on equity (TTM)
-18.12%
Valuation
Price to revenue (TTM)
3.544
Price to book
10.02
Price to tangible book (TTM)
-94.04
Price to free cash flow (TTM)
1,197.263
Free cash flow yield (TTM)
0.08%
Free cash flow per share (TTM)
0.53%
Growth
Revenue change (TTM)
28.25%
Earnings per share change (TTM)
-80.52%
3-year revenue growth (CAGR)
19.56%
10-year revenue growth (CAGR)
92.73%
3-year earnings per share growth (CAGR)
-53.78%
10-year earnings per share growth (CAGR)
-20.38%
What the Analysts think about FOLD
Analyst ratings (Buy, Hold, Sell) for Amicus Therapeutics stock.
Bulls say / Bears say
Amicus Therapeutics has entered into an exclusive license agreement with Dimerix for DMX-200, targeting Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease, with potential milestone payments up to $560 million and tiered royalties, indicating significant future revenue streams. (stocktitan.net)
The company's lead therapy, Galafold, is the only approved oral treatment for Fabry disease, positioning Amicus as a leader in this niche market. (stockanalysis.com)
Analysts have set a consensus price target of $16.75 for Amicus Therapeutics, suggesting potential upside from current trading levels. (americanbankingnews.com)
Wells Fargo & Company issued a pessimistic forecast for Amicus Therapeutics' stock price, potentially indicating concerns about future performance. (defenseworld.net)
Oppenheimer Asset Management Inc. reduced its holdings in Amicus Therapeutics by 29.5% during the fourth quarter, which may reflect decreased confidence among institutional investors. (defenseworld.net)
The company's stock has experienced a decline, with a 1.8% drop noted in recent trading, possibly indicating market concerns. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
FOLD Financial Performance
Revenues and expenses
FOLD Earnings Performance
Company profitability
FOLD News
AllArticlesVideos
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
GlobeNewsWire·2 weeks ago
U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts
GlobeNewsWire·3 weeks ago
The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amicus Therapeutics stock?
Amicus Therapeutics (FOLD) has a market cap of $1.9B as of July 11, 2025.
What is the P/E ratio for Amicus Therapeutics stock?
The price to earnings (P/E) ratio for Amicus Therapeutics (FOLD) stock is 0 as of July 11, 2025.
Does Amicus Therapeutics stock pay dividends?
No, Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Amicus Therapeutics dividend payment date?
Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders.
What is the beta indicator for Amicus Therapeutics?
Amicus Therapeutics (FOLD) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.